Table 2 Tumor response (n = 25)
Variables | mRECIST (n = 25) | RECIST 1.1 (n = 25) |
|---|---|---|
Best objective response | ||
 Complete response | 0 (0.0%) | 0 (0.0%) |
 Partial response | 11 (44.0%) | 9 (36.0%) |
 Stable disease | 5 (20.0%) | 7 (28.0%) |
 Progressive disease | 9 (36.0%) | 9 (36.0%) |
Objective response rate, n % | 11 (44.0%) | 9 (36.0%) |
Disease control rate, n,% | 16 (64.0%) | 16 (64.0%) |
TTR, months, median (95% CI) | 1.83 (1.40–2.27) | 1.73 (1.44–2.03) |
DOR, months, median (95% CI) | 8.43 (1.09–15.78) | 6.90 (2.73–11.07) |
PFS, months, median (95% CI) | 4.87 (2.07–7.66) | 4.33 (2.07–6.60) |
 6-month PFS rate | 38.8% | 34.7% |
 12-month PFS rate | 23.3% | 24.0% |
Liver-specific PFS, months, median (95% CI) | 5.47 (2.20–8.74) | 4.87 (2.09–7.65) |
 6-month PFS rate | 42.9% | 34.7% |
 12-month PFS rate | 22.7% | 24.0% |
 18-month PFS rate | 22.7% | 24.0% |